Why Is Ceruloplasmin Low in Wilson’s Disease?

Ceruloplasmin runs low in Wilson’s disease because the protein never gets loaded with copper before it leaves the liver. The copper transporter responsible for that loading step, a protein called ATP7B, is defective in Wilson’s disease. Without its copper atoms, ceruloplasmin is structurally unstable and breaks down in the bloodstream far faster than normal. The result is a characteristic drop in circulating ceruloplasmin that clinicians have used as a diagnostic marker for decades, though the biology behind the drop and the diagnostic reality are both more nuanced than they first appear.

What Ceruloplasmin Actually Is

Ceruloplasmin is a large protein made by the liver and released into the blood. It has a distinctive blue color because it carries copper atoms within its structure. A fully assembled, copper-loaded ceruloplasmin molecule holds six copper atoms distributed across its six structural domains. Three of these copper atoms sit individually within domains 2, 4, and 6, while the remaining three cluster together at the junction of domains 1 and 6, forming a catalytic site that gives the protein its enzyme-like activity.¹ Those copper atoms are not passengers. They are integral to the protein’s shape and stability. The cluster at the domain 1–6 interface appears to act as a structural anchor that helps the protein fold correctly in the first place.¹

This is the key to understanding why ceruloplasmin drops in Wilson’s disease. The copper-free version of the protein, called apo-ceruloplasmin, is not just an “empty” version of the same molecule. It is a fundamentally less stable molecule that the body clears from the blood much more quickly. When the copper-loaded form (holo-ceruloplasmin) cannot be made properly, apo-ceruloplasmin gets secreted instead, and it vanishes from the bloodstream before standard tests can detect much of it.

The Role of ATP7B in Copper Loading

The protein at the center of Wilson’s disease is ATP7B, a copper-transporting enzyme that sits in a compartment of liver cells called the trans-Golgi network. ATP7B has two jobs. First, it moves copper into the secretory pathway so that it can be incorporated into apo-ceruloplasmin, turning it into the stable, functional holo-ceruloplasmin that then gets released into the blood.² Second, when copper levels inside the cell rise, ATP7B relocates from its usual position and shuttles excess copper toward the bile ducts for excretion.³

Wilson’s disease arises from mutations in the gene that encodes ATP7B. When ATP7B is absent or nonfunctional, both of its jobs fail simultaneously. Copper cannot be loaded into ceruloplasmin before it leaves the liver, and copper cannot be excreted into bile. The consequences of these two failures are very different. The ceruloplasmin failure is what drops the blood level of the protein. The biliary excretion failure is what causes copper to accumulate dangerously in the liver, brain, and other organs.³ The low ceruloplasmin is essentially a byproduct of the same genetic defect that causes the disease, rather than a direct cause of the copper toxicity itself.

Why Low Ceruloplasmin Matters Beyond Diagnosis

You might wonder whether the drop in ceruloplasmin causes any problems on its own, separate from the copper overload. The answer is yes, at least indirectly, because ceruloplasmin has an important day job unrelated to copper transport. It functions as a ferroxidase, meaning it helps convert iron from one chemical form to another so that iron can be loaded onto the blood’s main iron-carrying protein, transferrin. Ceruloplasmin works in tandem with ferroportin, a channel that lets iron out of cells. Without ceruloplasmin’s help, iron can get stuck inside cells or fail to be properly distributed.⁴ A related ferroxidase called hephaestin handles a similar job in the intestine for dietary iron absorption.⁵

In Wilson’s disease, the iron-metabolism consequences of low ceruloplasmin are generally overshadowed by the much more dramatic effects of copper toxicity. But the connection matters clinically because a rare, entirely separate condition called aceruloplasminemia, in which people produce essentially no ceruloplasmin at all, causes severe iron accumulation in the brain, liver, and pancreas. That condition is a pure illustration of what happens when ceruloplasmin’s ferroxidase function is completely absent. Wilson’s disease patients still make some ceruloplasmin and retain some ferroxidase activity, but the overlap in biology is worth knowing about.

Ceruloplasmin in the Brain

The ceruloplasmin measured in blood tests is the soluble form secreted by the liver. But there is also a version of ceruloplasmin that never enters the bloodstream. In the brain, astrocytes produce a form of ceruloplasmin that is anchored directly to their cell surfaces. This membrane-bound version is generated through a different processing step during the gene’s expression, a kind of alternative assembly route that tethers the protein to the cell membrane instead of releasing it.⁶

This brain-anchored ceruloplasmin presumably serves the same ferroxidase role locally, helping astrocytes manage iron. Its existence raises an interesting question for Wilson’s disease: since the brain form is made locally by astrocytes rather than imported from the liver, its production may not depend on ATP7B in the same way. The neurological damage in Wilson’s disease is thought to come primarily from copper accumulation in the brain rather than from a local ceruloplasmin deficit, but the interplay between copper overload and iron handling in brain tissue remains an active area of research.

Why the Standard Diagnostic Cutoff Is Problematic

Clinicians have long used a blood ceruloplasmin level below 0.20 g/L (or equivalently, 20 mg/dL) as a flag for Wilson’s disease. The problem is that this cutoff casts too wide a net. In a large Chinese study of over 3,000 patients, the conventional 0.20 g/L threshold correctly identified nearly all Wilson’s disease patients but also flagged about 30% of non-Wilson’s patients as false positives.⁷ Among those false positives, the most common causes were other forms of hepatitis, liver failure, nephrotic syndrome, and people who carried one copy of the Wilson’s disease gene without having the disease. People with liver failure were especially likely to have ceruloplasmin below 0.20 g/L, with about two-thirds falling below that line.⁷

Lowering the diagnostic cutoff improves accuracy substantially. That same study found that a cutoff of 0.13 g/L maintained about 97% sensitivity while pushing specificity above 96%.⁷ An independent hospital-based study reached similar conclusions, finding that 150 mg/L (0.15 g/L) as a cutoff delivered higher overall accuracy than the traditional 200 mg/L.⁸ A genotype-confirmed study found that a threshold of 0.14 g/L achieved perfect sensitivity and specificity in its validation group, and that none of 690 healthy people with ceruloplasmin below 0.20 g/L had levels below 0.14 g/L.⁹

Wilson’s disease patients typically have ceruloplasmin levels far below even these revised thresholds. European clinical guidelines note that the level is usually lower than 0.1 g/L.¹⁰ A pediatric study found the average in affected children was around 5.7 mg/dL, compared with about 25.6 mg/dL in carriers who had one mutated gene copy.¹¹ Despite its usefulness, a ceruloplasmin test alone is not enough to confirm or rule out the diagnosis.¹⁰ Clinicians combine it with urine copper levels, liver copper content, genetic testing, and clinical signs like Kayser-Fleischer rings in the eyes.

The Measurement Method Changes What You See

There is a subtle but clinically meaningful wrinkle in how ceruloplasmin is measured. Most routine labs use an immunological method, which detects the ceruloplasmin protein regardless of whether it has copper in it. This means the test picks up both the functional holo-ceruloplasmin and the copper-free apo-ceruloplasmin.¹² In Wilson’s disease, where the liver secretes ceruloplasmin without its copper, the immunological test can register a higher reading than you would expect, because it counts the nonfunctional apo-ceruloplasmin that is still circulating before it degrades.

An alternative approach is to measure ceruloplasmin’s enzymatic (oxidase) activity, which only registers the copper-loaded, biologically active form. Because Wilson’s disease patients secrete ceruloplasmin that lacks copper, their enzymatic activity is very low even if the immunological assay picks up some residual protein.¹² In other words, the enzymatic assay tends to be a sharper diagnostic tool because it zeroes in on the specific failure that Wilson’s disease causes. The immunological assay can occasionally indicate a normal-ish level of ceruloplasmin while the enzymatic activity is actually very low, which risks a missed diagnosis.¹³ This is one practical reason why clinicians are warned not to rely on ceruloplasmin alone.

Other Reasons Ceruloplasmin Can Be Low

Wilson’s disease is the most discussed cause of low ceruloplasmin, but it is far from the only one. Any condition that impairs the liver’s ability to make proteins can drag ceruloplasmin down. Severe liver disease from any cause, including viral hepatitis and alcohol-related cirrhosis, can lower it enough to overlap with Wilson’s disease levels. As noted earlier, roughly two-thirds of patients with liver failure in one large study had ceruloplasmin below 0.20 g/L.⁷

Protein-energy malnutrition is another recognized cause, since the liver needs adequate nutrition to synthesize ceruloplasmin at normal rates. Nephrotic syndrome can lower ceruloplasmin too, because the kidneys leak large amounts of protein into the urine. And Menkes disease, a different genetic copper disorder, also produces low ceruloplasmin, but through an entirely different mechanism: mutations in a cousin transporter called ATP7A prevent copper from being absorbed in the intestine in the first place, creating a systemic copper deficiency.¹⁴ Without enough copper in the body, the liver cannot load ceruloplasmin regardless of how well ATP7B works. Wilson’s disease and Menkes disease therefore produce the same lab finding for opposite underlying reasons: Wilson’s disease traps copper inside cells because the liver cannot export it, while Menkes disease starves the body of copper because the gut cannot absorb it.

What About Carriers

Wilson’s disease is an autosomal recessive condition, meaning you need two defective copies of the ATP7B gene to develop the disease. People who carry one defective copy and one normal copy are called heterozygous carriers. Their ceruloplasmin levels sit in an interesting middle ground. In one pediatric study, carriers averaged about 25.6 mg/dL, well above the levels seen in affected patients but noticeably below typical healthy values for that study population.¹¹

However, a study of adult Icelandic carriers found no statistically significant difference in ceruloplasmin concentration or oxidase activity between carriers and matched controls, though there was a slight trend toward lower values in the carriers.¹⁵ The picture for carriers, then, is that one working copy of ATP7B is generally sufficient to maintain ceruloplasmin within the normal range, but some carriers may drift toward the lower end. This is relevant clinically because carriers occasionally get caught by the broad 0.20 g/L cutoff and can be mistakenly flagged as having Wilson’s disease. The tighter cutoffs discussed earlier help avoid that misclassification.

Detecting Wilson’s Disease at Birth

Because Wilson’s disease is genetic and present from birth, researchers have explored whether ceruloplasmin testing could be incorporated into newborn screening programs. One study looked at archived newborn blood spots from patients later diagnosed with Wilson’s disease and found that their ceruloplasmin levels at birth were already significantly lower than those of unaffected newborns.¹⁶ The affected infants had levels around 2.6 to 2.8 mg/dL in their dried blood spots.

This finding suggests that the ATP7B defect affects ceruloplasmin loading from the very beginning of life, not just once copper starts accumulating. It makes biological sense: if the transporter is broken, copper cannot be incorporated into ceruloplasmin at any age. The challenge for newborn screening is practical rather than biological. Ceruloplasmin levels in all newborns are naturally lower and more variable than in older children and adults, which makes it harder to draw a reliable line between affected and unaffected babies. No country has yet adopted universal ceruloplasmin-based newborn screening for Wilson’s disease, but the concept remains under investigation, especially as more sensitive testing methods develop.

What Happens to All That Unbound Copper

If ceruloplasmin normally carries most of the copper in blood, you might expect that Wilson’s disease patients, with their low ceruloplasmin, would have low total blood copper as well. And paradoxically, total serum copper often is low in Wilson’s disease, because ceruloplasmin-bound copper makes up such a large fraction of the total in healthy people. But the fraction that is not bound to ceruloplasmin, sometimes called “free” copper, is dramatically elevated. This unbound copper circulates loosely attached to albumin and other molecules, and it is toxic.¹⁷

In fulminant Wilson’s disease, the most severe presentation, a massive release of copper from a damaged liver floods the bloodstream. This free copper damages red blood cell membranes, causing them to rupture in a process called intravascular hemolysis. It also injures the kidneys.¹⁷ The combination of liver failure, hemolytic anemia, and kidney injury in a young person is a recognized clinical pattern that should prompt urgent testing for Wilson’s disease. In these emergencies, the ceruloplasmin level is virtually undetectable, and the ratio of free copper to total copper is markedly abnormal.

The low ceruloplasmin, then, is not just a diagnostic curiosity. It reflects the fundamental biochemical failure that defines the disease: copper cannot be properly handled by the liver. Understanding why the number is low, rather than simply memorizing that it is, connects the lab result to the copper toxicity that drives every clinical feature of Wilson’s disease, from liver cirrhosis and tremors to psychiatric symptoms and those characteristic golden-brown Kayser-Fleischer rings in the cornea.

1
PubMed. Discrete roles of copper ions in chemical unfolding of human ceruloplasmin
2
PubMed Central. Intracellular trafficking of the human Wilson protein: the role of the six N-terminal metal-binding sites
3
PubMed. Copper-induced apical trafficking of ATP7B in polarized hepatoma cells provides a mechanism for biliary copper excretion
4
PubMed Central. Ceruloplasmin-ferroportin system of iron traffic in vertebrates
5
PubMed. Unexpected role of ceruloplasmin in intestinal iron absorption
6
PubMed. Alternative RNA splicing generates a glycosylphosphatidylinositol-anchored form of ceruloplasmin in mammalian brain
7
PubMed Central. Role of serum ceruloplasmin in the diagnosis of Wilson’s disease: A large Chinese study
8
PLoS ONE. The optimal threshold of serum ceruloplasmin in the diagnosis of Wilson’s disease: A large hospital-based study
9
PubMed. Diagnostic accuracy of serum ceruloplasmin in Wilson disease: determination of sensitivity and specificity by ROC curve analysis among ATP7B-genotyped subjects
10
Journal of Hepatology. EASL Clinical Practice Guidelines: Wilson’s disease
11
PubMed Central. Assessment of the diagnostic value of serum ceruloplasmin for Wilson’s disease in children
12
Journal of Hepatology. Serum ceruloplasmin oxidase activity is a sensitive and highly specific diagnostic marker for Wilson disease
13
PubMed. Value of an enzymatic assay for the determination of serum ceruloplasmin
14
Rosenberg’s Molecular and Genetic Basis of Neurological and Psychiatric Disease. Menkes disease and other ATP7A disorders
15
PubMed Central. Ceruloplasmin and superoxide dismutase (SOD1) in heterozygotes for Wilson disease: A case control study
16
PubMed. Retrospective determination of ceruloplasmin in newborn screening blood spots of patients with Wilson disease
17
PubMed Central. Fulminant Wilson’s Disease Managed with Plasmapheresis as a Bridge to Liver Transplant